Comparing Eli Lilly and (LLY) & The Competition

Eli Lilly and (NYSE: LLY) is one of 116 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Eli Lilly and to similar businesses based on the strength of its profitability, dividends, institutional ownership, analyst recommendations, earnings, risk and valuation.

Risk and Volatility

Eli Lilly and has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, Eli Lilly and’s competitors have a beta of 0.90, suggesting that their average stock price is 10% less volatile than the S&P 500.

Earnings and Valuation

This table compares Eli Lilly and and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Eli Lilly and $22.00 billion $5.99 billion 38.83
Eli Lilly and Competitors $8.08 billion $2.63 billion 0.05

Eli Lilly and has higher revenue and earnings than its competitors. Eli Lilly and is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

75.7% of Eli Lilly and shares are owned by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.2% of Eli Lilly and shares are owned by company insiders. Comparatively, 12.0% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Eli Lilly and and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eli Lilly and 1 6 10 0 2.53
Eli Lilly and Competitors 844 3780 6810 185 2.55

Eli Lilly and currently has a consensus price target of $90.94, indicating a potential upside of 10.98%. As a group, “Pharmaceuticals” companies have a potential upside of 23.81%. Given Eli Lilly and’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Eli Lilly and has less favorable growth aspects than its competitors.

Dividends

Eli Lilly and pays an annual dividend of $2.08 per share and has a dividend yield of 2.5%. Eli Lilly and pays out 98.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Pharmaceuticals” companies pay a dividend yield of 2.5% and pay out 66.0% of their earnings in the form of a dividend. Eli Lilly and has increased its dividend for 2 consecutive years.

Profitability

This table compares Eli Lilly and and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eli Lilly and 9.90% 30.72% 11.09%
Eli Lilly and Competitors -2,859.89% -68.22% -9.44%

Summary

Eli Lilly and beats its competitors on 9 of the 15 factors compared.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company’s human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company’s animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit